DIAGNOS (TSXV-ADK) (OTCQB-DGNOF) uses its CARA (Computer Assisted Retina Analysis) AI platform for the diagnosis and grading of retinopathy as well as for certain specified future developments of the platform for a variety of applications (e.g., macular degeneration, glaucoma, stroke and enhanced analysis of wide-field retinal images). Diabetic retinopathy is silently blinding millions of people. The diabetic retinopathy market size was valued at USD $8 billion in 2018 and expected to grow 6.9% CAGR in 2019 to 2025.
DIAGNOS is FDA cleared, ISO certified, Health Canada licensed and apply their AI technology from studies of 16 countries, 140 clinics and over 400,000 patients. DIAGNOS’ technology is very precise and can do thousands of images a day. The automated detection and triage help reduce healthcare labour requirements while increasing patient access to quality care and reducing healthcare expenditures. DIAGNOS is on the path to global adoption and redefining the standard of eye care.
DIAGNOS has entered into a Memorandum of Understanding (MoU) for a potential worldwide distribution agreement for its CARA AI platform with the instruments division of Essilor International, a subsidiary of EssilorLuxottica, the world’s largest eyecare company. Although this is not yet a binding agreement, it does represent a potential base case of $13 – $67M+ in peak sales opportunity for DIAGNOS.
DIAGNOS Inc. has 65M shares outstanding.